1. Home
  2. BIRK vs BLCO Comparison

BIRK vs BLCO Comparison

Compare BIRK & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birkenstock Holding plc

BIRK

Birkenstock Holding plc

SELL

Current Price

$34.32

Market Cap

5.5B

Sector

N/A

ML Signal

SELL

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

SELL

Current Price

$16.64

Market Cap

6.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BIRK
BLCO
Founded
1774
1853
Country
United Kingdom
Canada
Employees
N/A
N/A
Industry
Ophthalmic Goods
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
6.1B
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
BIRK
BLCO
Price
$34.32
$16.64
Analyst Decision
Buy
Buy
Analyst Count
23
15
Target Price
★ $50.32
$19.39
AVG Volume (30 Days)
★ 1.7M
472.7K
Earning Date
08-13-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $5,101,000,000.00
Revenue This Year
$11.98
$7.68
Revenue Next Year
$13.81
$5.95
P/E Ratio
$17.48
★ N/A
Revenue Growth
N/A
★ 6.47
52 Week Low
$29.93
$14.44
52 Week High
$50.73
$18.92

Technical Indicators

Market Signals
Indicator
BIRK
BLCO
Relative Strength Index (RSI) 52.80 45.01
Support Level $33.06 $15.89
Resistance Level $37.29 $16.58
Average True Range (ATR) 1.07 0.47
MACD 0.34 -0.07
Stochastic Oscillator 45.21 52.22

Price Performance

Historical Comparison
BIRK
BLCO

About BIRK Birkenstock Holding plc

Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: